Alphacalcidol

Phase 2Small molecule

UUniversity of Ioannina

Alphacalcidol is one of 22 small molecule programs targeting Scoliosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ScoliosisActive, not recruiting

ScoliosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Scoliosis

#DrugCompanyPhaseTrials

MS Contin

HHikma Pharmaceuticals LLC

Approved

3 2

Cyklokapron

AAmring

Approved

2 3

Marcaine

IInnocoll

Approved

1 4

Spravato

WWim Janssens

Approved

1 5

Catapres

Boehringer Ingelheim

Approved

—6

Cleviprex

Chiesi Farmaceutici S.p.A.

Approved

—7

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

1 8

Dolophine

HHikma Pharmaceuticals LLC

Phase 3

1 9

Neurontin

VViatris Specialty LLC

Phase 3

1 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Scoliosis1 trial

The Role of VitD in Rehabilitation of Idiopathic Adolescent Scoliosis

Recruiting·UUniversity of Ioannina·Phase 2·NCT03582917·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Alphacalcidol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alphacalcidol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alphacalcidol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Ioannina company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Ioannina

Alphacalcidol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Scoliosis1 trial

References

Drug Info

Quick Facts

Related News